



(11) **EP 3 575 326 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) International Patent Classification (IPC):
C07K 19/00 ^(2006.01) **A61K 38/16** ^(2006.01)
A61K 38/45 ^(2006.01) **A61P 35/02** ^(2006.01)
C07K 14/705 ^(2006.01) **C07K 16/00** ^(2006.01)
C12N 15/62 ^(2006.01) **A61K 38/00** ^(2006.01)

(48) Corrigendum issued on:
25.05.2022 Bulletin 2022/21

(52) Cooperative Patent Classification (CPC):
C07K 14/70503; A61P 35/00; A61P 35/02;
A61P 43/00; A61K 38/00; C07K 2319/30

(45) Date of publication and mention
of the grant of the patent:
13.04.2022 Bulletin 2022/15

(21) Application number: **19185175.7**

(22) Date of filing: **17.12.2013**

(54) **TREATMENT OF CD47+ DISEASE CELLS WITH SIRP ALPHA-FC FUSIONS**

BEHANDLUNG VON CD47+-KRANKHEITSZELLEN MIT SIRP-ALPHA-FC-FUSIONEN

TRAITEMENT DE CELLULES TUMORALES À CD47+ AVEC DES FUSIONS SIRP ALPHA/FC

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

- **SLAVOVA-PETROVA, Penka Slavtcheva**
Toronto, Ontario M8V 3X1 (CA)
- **PANG, Xinli**
Brampton, Ontario L6R 3H1 (CA)

(30) Priority: **17.12.2012 US 201261738008 P**

(74) Representative: **Script IP Limited**
Turnpike House
18 Bridge Street
Frome Somerset BA11 1BB (GB)

(43) Date of publication of application:
04.12.2019 Bulletin 2019/49

(60) Divisional application:
22162692.2

(56) References cited:
WO-A1-2009/046541 WO-A1-2010/130053

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
13865442.1 / 2 931 752

- **A. NEIL BARCLAY ET AL: ") and CD47: Structure,**
Function, and Therapeutic Target", ANNUAL
REVIEW OF IMMUNOLOGY, vol. 32, no. 1, 21
March 2014 (2014-03-21) , pages 25-50,
XP055166307, ISSN: 0732-0582, DOI:
10.1146/annurev-immunol-032713-120142

(73) Proprietor: **Trillium Therapeutics ULC**
Mississauga, Ontario L5L 1J9 (CA)

(72) Inventors:
• **UGER, Robert Adam**
Richmond Hill, Ontario L4C 7S4 (CA)

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 575 326 B8